[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glucose-metabolism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glucose-metabolism":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,53,79,105,133,161,195],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100641110","sucromet-nutritional-intervention-trial-100641110",false,"NCT07656298","SucroMet Nutritional Intervention Trial","SucroMet' Nutritional Intervention: Study of the Metabolic Impact of Sucrose (Natural Sugar) and Sucralose (Artificial Sweetener) Intake at Different Doses and Modes of Consumption in Adults With Normal Weight, Overweight, and Obesity","Inclusion Criteria:\n\n* Adults aged 18 to 65 years at the time of enrollment.\n* Body Mass Index (BMI) between 18.5 and 39.9 kg\u002Fm².\n* Men and women who report a preference for sweet taste and habitual consumption of sugar and\u002For sweeteners.\n* Individuals in good general health, as determined by:\n\n  1. Medical history and clinical evaluation;\n  2. Absence of uncontrolled chronic diseases, such as diabetes, metabolic syndrome, severe hypertension, or advanced liver or renal disease; and\n  3. Baseline biochemical parameters within normal reference ranges, including fasting plasma glucose \\\u003C100 mg\u002FdL, HbA1c \\\u003C5.7%, normal liver and renal function (ALT\u002FAST and creatinine within reference ranges), and blood pressure \\\u003C140\u002F90 mmHg without pharmacological treatment.\n* Less than 4 hours per week of moderate-to-vigorous physical activity.\n* Not following special or restrictive diets (e.g., ketogenic, strict vegetarian, or vegan diets).\n* Not taking medications known to affect metabolism, including, for example, antidiabetic drugs, systemic corticosteroids, weight-loss medications, or high-dose antioxidant supplements, except for stable use of hormonal contraceptives.\n* Willingness to maintain habitual diet and physical activity throughout the study, with the only modification being the assigned sweetener intervention.\n* Ability and willingness to comply with all study procedures and scheduled visits.\n* Provision of written informed consent before participation.\n\nExclusion Criteria:\n\n* Gastrointestinal disorders influencing digestion or nutrient absorption (e.g., inflammatory bowel disease, celiac disease, malabsorption syndromes).\n* History of cancer not in remission.\n* Uncontrolled thyroid disorders.\n* History of bariatric surgery or extreme weight loss within the past 12 months.\n* Pregnancy, breastfeeding, or planning pregnancy during the study period.\n* Acute illness, major infection, hospitalization, or major surgery within the previous 6 months.\n* Any condition that, in the investigators' judgment, could compromise participant safety, protocol adherence, or interpretation of the study results.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","SucroMet is designed to evaluate how adding two commonly used sweeteners-sucrose (table sugar) and sucralose (a low-calorie sweetener)-at low and high doses may influence glucose regulation, including insulin resistance and fasting plasma glucose, in adults aged 18 to 65 years with normal weight, overweight, or obesity.\n\nThe low-dose intervention consists of 5% of the Estimated Energy Requirement (EER) from sucrose or 5 sucralose tablets per day (approximately 33.35 mg\u002Fday of sucralose). The high-dose intervention consists of 10% of EER from sucrose or 10 sucralose tablets per day (approximately 66.7 mg\u002Fday of sucralose). These doses maintain the planned 1:2 exposure ratio between the low- and high-dose intervention groups.\n\nBefore the intervention begins, participants' habitual dietary intake is assessed and, when necessary, minor dietary adjustments are made to support a stable overall eating pattern while maintaining energy intake. Participants then complete a four-week run-in period during which these recommendations are followed, and dietary records are used to verify dietary stability before the intervention starts.\n\nParticipants will consume the assigned sweetener incorporated into foods or beverages that they already consume as part of their habitual diet, without substantial changes to their usual eating patterns. The intervention includes two consecutive 12-week phases, one involving solid food intake and the other involving liquid intake, separated by a two-week washout period. This design allows evaluation of the effects of sweetener type, dose, and mode of consumption.\n\nThe primary outcomes are changes in glucose regulation, including fasting plasma glucose and insulin resistance assessed by HOMA-IR. Secondary outcomes include changes in body composition, anthropometric measurements, blood pressure, routine biochemical parameters, gut microbiota composition, DNA methylation patterns in peripheral blood cells, and biomarkers related to inflammation, oxidative stress, and metabolomic profiles measured in blood and urine.\n\nParticipants will attend scheduled study visits for anthropometric assessments, dietary evaluations, and biological sample collection. Blood, urine, and stool samples will be obtained at baseline and after each intervention phase.\n\nThe study aims to address the following questions:\n\n1. Do metabolic responses to sucrose and sucralose, including changes in insulin resistance (HOMA-IR) and fasting plasma glucose, differ according to participants' body mass index (BMI)?\n2. Do low and high doses of sucrose and sucralose differentially affect glucose regulation, body composition, and metabolic health?\n3. Does the mode of intake (solid versus liquid) influence changes in gut microbiota composition?\n4. Are changes in DNA methylation patterns in peripheral blood cells associated with the consumption of sucrose and sucralose at different doses and in different forms?\n5. Do different doses of sucrose and sucralose influence biomarkers related to inflammation, oxidative stress, and metabolomic profiles?",[28,29],"Overweight , Obesity","Glucose Metabolism",[31,32,33,34,29,35,36,37,38,39],"Sucrose","Sucralose","Sweeteners","Body Composition","Gut Microbiota","DNA Methylation","Inflammation","Oxidative Stress Biomarkers","Nutritional Intervention","RECRUITING","2026-06-15",{"date":43,"type":44},"2026-06-18","ACTUAL",{"date":46,"type":22},"2026-07",{"date":48,"type":22},"2027-09",{"name":50,"class":51},"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":52},"100634747","glucose-level-during-endurance-exercise-100634747","NCT07543705","Glucose-Level During Endurance Exercise","Glucose-Level During Endurance Exercise (GLEE Study): Influencing Factors and Mechanisms","GLEE","Inclusion Criteria:\n\n* BMI between 18.5 and 30 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* cardiovascular disease\n* vegan diet\n* drug or alcohol abuse\n* Drug therapy that raises or lowers blood sugar, e.g. steroids, antidiabetics, insulin or influences the autonomic nervous system\n* No consent to be informed about incidentally discovered pathological findings\n* Any other (clinical) condition that would endanger participants safety or question scientific success according to the physicians opinion.",{"count":62,"type":22},100,"OBSERVATIONAL","As part of the mandatory annual assessment of physical fitness, soldiers are required to complete a standardized military march. A total of 100 healthy volunteer participants will be recruited from soldiers serving at the Bundeswehr Hospital Ulm. During this march, physiological and metabolic parameters will be assessed.\n\nAt baseline, anthropometric data and information on medical history, lifestyle, and fitness status will be collected, including a validated questionnaire on physical activity. Blood and urine samples will be obtained to determine routine laboratory and metabolic parameters, and body composition will be assessed using bioelectrical impedance analysis. In addition, selected sensors will be applied to continuously record physiological data.\n\nParticipants will then complete a 6 km march carrying 15 kg of equipment. After completion of the march, sensors will be removed and additional blood and urine samples will be collected to evaluate metabolic responses to physical exertion, including catecholamine levels.",[29],[67,68,69],"glucose levels","endurance exercise","continuous glucose monitoring","2026-05-06",{"date":72,"type":44},"2026-05-11",{"date":74,"type":44},"2026-05-05",{"date":76,"type":22},"2028-06",{"name":78,"class":51},"University of Ulm",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":16,"sex":17,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":52},"100594537","stable-isotopes--adults-with-obesity-100594537","NCT07020741","Stable Isotopes- Adults With Obesity","Assessing Metabolic Health With Stable Isotope Tracer Techniques in Adults With Obesity","Si-OBA","Inclusion Criteria:\n\n* ages 19-59\n* Obese \\>\u002F= 30 kg\u002Fm\\^2 and \\>\u002F= 102 cm for males and \\>\u002F= 88 cm for females\n* Godin Leisure-time or exercise questionnaire \\\u003C14 units\n\nExclusion Criteria:\n\n1. Pregnant or become pregnant\n2. Any known food allergies\n3. Smoker\n4. Are physically active\n5. Have any known metabolic diseases\n6. Have been weight unstable within the last 6 months (lost or gained \\>10% of body mass)\n7. Non eumenorrheic or on a hormonal birth control","19 Years","59 Years",{"count":90,"type":22},8,[25],"In a crossover design, 8 participants will receive caloric drinks containing stable isotopes. In one arm of the study, participants will consume 6 hourly drinks containing two stable isotopes. Repeated blood, breath, urine, and muscle biopsies will be taken. In the second arm, participants will consume 1 drink containing 75g glucose, labeled with two stable isotopes of glucose. Periodic blood and breath will be taken over three hours.",[94,29,95],"Obese Patients (BMI ≥ 30 kg\u002Fm²)","Protein Metabolism","2026-04-28",{"date":98,"type":44},"2026-04-29",{"date":100,"type":44},"2025-09-12",{"date":102,"type":22},"2026-12-31",{"name":104,"class":51},"University of Illinois at Urbana-Champaign",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":123,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":52},"100455859","genesis-genotype-guided---natriuretic-peptides---cardiometabolic-health-study-100455859","NCT05216042","GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study","Atrial Natriuretic Peptide and Regulation of Cardiometabolic Health: A Genotype-Guided Human Physiological Study","Inclusion Criteria:\n\n* Adults: Age more than or equal to 18; an equal number of Males and Females\n* Consent to the collection of genetic material\n* Willing to adhere to the study protocol\n\nExclusion Criteria:\n\n* Age \\\u003C18, at screening.\n* BMI \\>45 kg\u002Fm2.\n* Blood pressure more than 140\u002F90 mmHg.\n* Participants who are taking more than 2 hypertension medications.\n* History of diabetes or fasting plasma glucose \\>126 mg\u002Fdl or HbA1C\\>=6.5% or prior treatment with antidiabetic medication.\n* Have any past or present history of cardiovascular diseases (stroke, seizure, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia)\n* Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence);\n* Estimated GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2; albumin creatinine ratio ≥30 mg\u002Fg\n* Hepatic Transaminase (AST and ALT) levels \\>3x the upper limit of normal\n* Anemia (men, Hct \\\u003C 38%; women, Hct \\\u003C36%)\n* Inability to exercise on a treadmill",{"count":113,"type":22},200,[25],"Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have \\~30% lower levels of NP and are at a greater risk of developing cardiovascular (CV) events as compared to lean and White counterparts. Some people have common genetic variations that cause them to have \\~20% lower NP levels. Similar to other low NP populations, these individuals with low NP genotype (i.e., carrying a common genetic variation called rs5068) are at a greater risk of developing cardiometabolic diseases. By understanding the NP response following the exercise challenge and the glucose challenge in individuals with genetically lower NP levels will help us understand how to improve cardiometabolic health in them.",[117,118,119,120,29,121,122],"Cardiovascular Diseases","Natriuretic Peptides","Cardiometabolic Diseases","Energy Expenditure","Exercise","Obesity",[118,117,29,120,121,122],"2026-04-03",{"date":126,"type":44},"2026-04-09",{"date":128,"type":44},"2022-04-01",{"date":130,"type":22},"2027-04-30",{"name":132,"class":51},"University of Alabama at Birmingham",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":16,"sex":17,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":157,"leadSponsor":159,"locationsCount":52},"100619891","investigating-the-acute-effects-of-increasing-alanine-exposure-in-healthy-participants-100619891","NCT07350512","Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants","Investigating the Effect of Glucagon on Cognitive Function and Cerebral Glucose Metabolism in Humans: A Pilot Study","Inclusion Criteria:\n\n* Capable of understanding the participant information and signing the consent form\n* Between 25 and 70 years of age at the time of screening\n* Body mass index (BMI) ≤ 25 kg\u002Fm2 at the time of screening\n\nExclusion Criteria:\n\n* Enrolment in other research projects that might interfere with the study\n* Diabetes diagnosis (type 1 and 2)\n* Pregnancy or breastfeeding\n* Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol\n* Impaired liver function defined as either alanine aminotransferase (ALAT) and\u002For aspartate aminotransferase (ASAT) ≥ 2 times normal values\n* Kidney disease defined as serum creatinine levels ≥ 126 μmol\u002FL for male and ≥ 111 μmol\u002FL for female\n* Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic\n* Active or recent malignant disease\n* Current or history of severe alcohol use or drug\u002Fchemical abuse as per investigator's judgement\n* Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol","25 Years","70 Years",{"count":143,"type":22},15,[25],"In this study the investigators will investigate the acute effects of increasing alanine exposure on metabolic parameters in healthy participants.\n\nParticipants will participate in one study day. After initial baseline blood samples, a three-hour intravenous infusion with glucagon will be initiated. The infusion rate will be increased every 30 minutes.",[29,147],"Glucagon",[149,150,151],"Alanine","glucagon","glucose metabolism","NOT_YET_RECRUITING","2026-01-09",{"date":155,"type":44},"2026-01-20",{"date":155,"type":22},{"date":158,"type":22},"2027-01-20",{"name":160,"class":51},"Nicolai Jacob Wewer Albrechtsen",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":180,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100569921","standuptv-habits-feasibility-trial-for-maintaining-reductions-in-sedentary-screen-time-100569921","NCT06700525","StandUPTV Habits: Feasibility Trial for Maintaining Reductions in Sedentary Screen Time","SUTV Habits","Inclusion Criteria:\n\n* Insufficiently active as defined by not meeting current US National Guidelines for Physical Activity of 150 minutes of MVPA\u002Fweek (Measured by the Stanford\n* Leisure-Time Activity Categorical Item)\n* \\> 3 hours of SST per day\n* Use Android (8.0+) smartphone (8.0+ represents 95% of Android device coverage per https:\u002F\u002Fapilevels.com\u002F)\n* Have regular broadband internet in their home or an unlimited data plan\n* Able to read\u002Funderstand English (\\>5th grade literacy)\n* Willing to download StandUPTV Habits\n* Willing to wear activPAL and CGM device during study assessment periods\n* Willing to have data shared in de-identified form in Dexcom Clarity platform\n* Willing to be randomized to either study condition\n* Not traveling overnight or longer in the next 4 months\n\nExclusion Criteria:\n\n* Planned relocation\n* Current smoker\n* Have a major illness (e.g., heart disease, cancer, renal disease) for which MVPA is contraindicated\n* Diagnosed with diabetes or gestational diabetes in the past\n* Currently using a CGM\n* Pregnant\n* Occupation that requires substantial use of personal device for media-related activities (e.g., social media)\n* Drug abuse\n* Serious psychological disorder\n* Not willing to use Fitbit or smart plugs for calculation of sedentary screen time for functionality of StandUPTV app","23 Years","64 Years",{"count":171,"type":22},48,[25],"Our goal in this study is to further refine StandUPTV, an application designed to reduce SST in adults in our first study (ASU IRB # STUDY00012109), for the StandUPTV Habits program. This program aims to establish a non-sedentary habit triggered by an alert from the StandUPTV application after participants engage in approximately 30 minutes of SST in the evening.",[175,176,177,29,178,179],"Sedentary Behaviors","Screen Time","Physical Activity","Sleep Quality","HbA1c Level",[181,182,183,184],"sedentary behavior","action planning","evening sedentary screen time","mHealth","2026-01-08",{"date":187,"type":44},"2026-01-12",{"date":189,"type":44},"2025-07-01",{"date":191,"type":22},"2026-12-15",{"name":193,"class":51},"Arizona State University",2,{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":16,"sex":17,"minAge":202,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":52},"100560840","evaluation-of-biomarkers-for-predicting-macronutrient-intake-100560840","NCT06582381","Evaluation of Biomarkers for Predicting Macronutrient Intake","Microdialysis","Inclusion criteria\n\n* Ability to walk, sit down and stand up independently\n* Age 50-75 years old\n* Ability to lie in supine or slightly elevated position for approximately 13 hours\n* BMI between 25 and 35\n* Willingness and ability to comply with the protocol\n\nExclusion Criteria\n\n* Established diagnosis of malignancy\n* Established diagnosis of Insulin or non-Insulin Dependent Diabetes Mellitus\n* History of untreated metabolic diseases including hepatic or renal disorder\n* Currently on anticoagulants (i.e., warfarin, factor X inhibitors or direct thrombin inhibitors)\n* History of deep vein thrombosis, pulmonary embolisms, or known clotting disorders\n* Presence of acute illness or metabolically unstable chronic illness\n* Recent myocardial infarction (less than 1 year)\n* Known allergy or intolerance to any of the meal components\n* Any other condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient\n* Failure to give informed consent or Investigator\\'s uncertainty about the willingness or ability of the participant to comply with the protocol requirements","50 Years","75 Years",{"count":205,"type":22},33,[25],"The goal of this clinical trial is to establish the relationship between macronutrient food intake and the resulting blood and intersticial fluid (ISF )levels of small molecule markers, as well as, validate wearable optical readers and data fusion algorithms to accurately predict individual-specific macronutrient availability in real time.\n\nThe study involves 1 screening visit of approximately 2 hours and up to 4 study days of approximately 14 hours. Subjects will be asked to arrive in the fasted state on all study days. Fasting prior to screening is not required. On the screening visit, body weight, height, and body composition by Dual-energy X-ray absorptiometry (DXA) will be measured. In addition, habitual dietary intake, physical activity level (PASE), and quality of life (SGRQ-C) will be assessed.",[29,209],"Amino Acid Metabolism",[211,212,213,214,215,216,217,218],"amino acid","glucose","metabolism","microdialysis","nutrition","stable isotope","macronutrient","biomarker","2025-07-18",{"date":221,"type":44},"2025-07-20",{"date":223,"type":44},"2023-12-06",{"date":225,"type":22},"2026-12",{"name":227,"class":51},"Texas A&M University"]